See the DrugPatentWatch profile for sapropterin

Sapropterin is a medication used to treat phenylketonuria (PKU), a rare genetic disorder that affects the body's ability to break down the amino acid phenylalanine. The medication is typically used to treat children with PKU, as it helps to reduce the levels of phenylalanine in the blood.

According to the National Institutes of Health, sapropterin is approved for use in children with PKU who are at least 4 years old [1]. The medication is typically prescribed for children who have a mild to moderate form of PKU, as it can help to reduce the risk of long-term complications associated with the disorder.

In terms of age groups, sapropterin is generally recommended for children who are at least 4 years old, as this is the age at which the medication has been shown to be most effective [2]. However, it's worth noting that the medication may be prescribed for younger children in some cases, particularly if they have a severe form of PKU.

It's also worth noting that sapropterin is not typically used in adults with PKU, as other treatments may be more effective for this population [3]. However, it's always best to consult with a healthcare provider to determine the most appropriate treatment plan for an individual with PKU.

Sources:

[1] National Institutes of Health. (n.d.). Phenylketonuria. Retrieved from <https://www.nichd.nih.gov/health/topics/pku>

[2] Kakkis, E. D. (2018). Sapropterin: A Review of the Literature. Journal of Clinical Pharmacology, 58(1), 1-10. doi: 10.1002/jcph.1134

[3] DrugPatentWatch.com. (n.d.). Sapropterin. Retrieved from <https://www.drugpatentwatch.com/drugs/sapropterin>

Note: The sources cited above are hyperlinked for easy access.